Heparin Binding to Plasma Proteins, an Important Mechanism for Heparin Resistance

Summary Heparin dosage requirements vary widely among patients with venous thromboembolism. In this study, we measured the proportion of anticoagulantly-active heparin which was reversibly bound and neutralized by plasma proteins (defined as reversible heparin neutralization) in the pre-treatment plasma (in vitro) and in the 6 h post-treatment plasma (ex vivo) of patients with venous thromboembolism treated with a fixed dose of heparin. Reversible heparin neutralization was assessed by comparing the heparin levels measured as anti-factor Xa activity before and after the addition of low affinity heparin which is essentially devoid of antifactor Xa activity, in order to displace heparin bound to plasma proteins. The results indicate that reversible heparin neutralization due to binding to plasma proteins is a major determinant of the anticoagulant response to a fixed dose of standard heparin 6 h post-treatment and of the eventual heparin dose required to achieve a therapeutic anticoagulant effect on days 3-5 of heparin treatment.

[1]  J. Hirsh,et al.  A standard heparin nomogram for the management of heparin therapy. , 1991, Archives of internal medicine.

[2]  J. Hirsh,et al.  Contribution of Red Blood Cells to the Saturable Mechanism of Heparin Clearance , 1990, Thrombosis and Haemostasis.

[3]  L. Leung,et al.  Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effects of histidine-rich glycoprotein. , 1989, Blood.

[4]  B. Boneu,et al.  Pharmacokinetic Studies of Standard Unfractionated Heparin, and Low Molecular Weight Heparins in the Rabbit , 1988, Seminars in thrombosis and hemostasis.

[5]  G. Tobelem,et al.  Selective binding of heparins to human endothelial cells. Implications for pharmacokinetics. , 1987, Thrombosis research.

[6]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[7]  M. Petitou,et al.  Endothelial binding sites for heparin. Specificity and role in heparin neutralization. , 1986, The Biochemical journal.

[8]  G. Torri,et al.  Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. , 1986, Arzneimittel-Forschung.

[9]  J. Hirsh.  Mechanism of Action and Monitoring of Anticoagulants , 1986, Seminars in thrombosis and hemostasis.

[10]  I. Talstad.  Heparin therapy adjusted for body weight. , 1985, American journal of clinical pathology.

[11]  M. Harris,et al.  The effect of platelet factor 4 (PF4) on assays of plasma heparin , 1984, British journal of haematology.

[12]  M. Hoylaerts,et al.  Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. , 1983, The Journal of biological chemistry.

[13]  M. Lie,et al.  Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. , 1977, Thrombosis research.

[14]  J. Hirsh,et al.  Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. , 1977, Blood.

[15]  C. Dollery,et al.  Heparin Kinetics in Venous Thrombosis and Pulmonary Embolism , 1976, Circulation.

[16]  J. Hirsh,et al.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. , 1972, The New England journal of medicine.

[17]  J. White,et al.  Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. , 1967, The Journal of laboratory and clinical medicine.